{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:37:35Z","timestamp":1773142655520,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T00:00:00Z","timestamp":1424304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/hr.2015.12","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T06:54:30Z","timestamp":1424328870000},"page":"308-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review"],"prefix":"10.1038","volume":"38","author":[{"given":"Chisa","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kaneshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Minakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,19]]},"reference":[{"key":"BFhr201512_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","volume":"60","author":"M Bullo","year":"2012","unstructured":"Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD . Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60: 444\u2013450.","journal-title":"Hypertension"},{"key":"BFhr201512_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.earlhumdev.2005.11.001","volume":"82","author":"A Quan","year":"2006","unstructured":"Quan A . Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82: 23\u201328.","journal-title":"Early Hum Dev"},{"key":"BFhr201512_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00125-010-2040-1","volume":"54","author":"M Porta","year":"2011","unstructured":"Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sj\u00f8lie AK, DIRECT Study Group. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia 2011; 54: 1298\u20131303.","journal-title":"Diabetologia"},{"key":"BFhr201512_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.reprotox.2011.02.008","volume":"31","author":"O Diav-Citrin","year":"2011","unstructured":"Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A . Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011; 31: 540\u2013545.","journal-title":"Reprod Toxicol"},{"key":"BFhr201512_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/HJH.0b013e328341885d","volume":"29","author":"VJ Karthikeyan","year":"2011","unstructured":"Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG . Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011; 29: 396\u2013399.","journal-title":"J Hypertens"},{"key":"BFhr201512_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1476-5381.1996.tb15999.x","volume":"119","author":"AJ Forhead","year":"1996","unstructured":"Forhead AJ, Whybrew K, Hughes P, Broughton Pipkin F, Sutherland M, Fowden AL . Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation. Br J Pharmacol 1996; 119: 393\u2013401.","journal-title":"Br J Pharmacol"},{"key":"BFhr201512_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-0030-1269895","volume":"223","author":"C H\u00fcnseler","year":"2011","unstructured":"H\u00fcnseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, K\u00f6rber F, Schmitt K, Welzing L, M\u00fcller A, Herkenrath P, Hoppe B, Gortner L, Roth B, Kattner E, Schaible T . Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr 2011; 223: 10\u201314.","journal-title":"Klin Padiatr"},{"key":"BFhr201512_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s00467-005-1937-2","volume":"20","author":"M Bald","year":"2005","unstructured":"Bald M, Holder M, Zieger M, Vochem M, Leichter HE . Increased renal echogenicity in a preterm neonate: question and answer. Pediatr Nephrol 2005; 20: 1664\u20131668.","journal-title":"Pediatr Nephrol"},{"key":"BFhr201512_CR9","first-page":"313","volume":"23","author":"JK Bass","year":"2006","unstructured":"Bass JK, Faix RG . Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. Am J Pathol 2006; 23: 313\u2013317.","journal-title":"Am J Pathol"},{"key":"BFhr201512_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/bdra.20047","volume":"70","author":"N Berkane","year":"2004","unstructured":"Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S . Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 2004; 70: 547\u2013549.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"BFhr201512_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1345\/aph.1E250","volume":"39","author":"M-A Bos-Thompson","year":"2005","unstructured":"Bos-Thompson M-A, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D . Fetal toxic effects of angiotensin II receptor antagonists: Case report and follow-up after birth. Ann Pharmacother 2005; 39: 157\u2013161.","journal-title":"Ann Pharmacother"},{"key":"BFhr201512_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1345\/aph.1A013","volume":"35","author":"GG Briggs","year":"2001","unstructured":"Briggs GG, Nageotte MP . Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001; 35: 859\u2013861.","journal-title":"Ann Pharmacother"},{"key":"BFhr201512_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00467-007-0618-8","volume":"23","author":"C Celentano","year":"2008","unstructured":"Celentano C, Prefumo F, di Vera E, Iannicco A, Gallo DP, Liberati M . Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol 2008; 23: 333\u2013334.","journal-title":"Pediatr Nephrol"},{"key":"BFhr201512_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/j.1471-0528.2003.02139.x","volume":"110","author":"RM Cox","year":"2003","unstructured":"Cox RM, Anderson JM, Cox P . Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. BJOG 2003; 110: 1038\u20131040.","journal-title":"BJOG"},{"key":"BFhr201512_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00467-006-0070-1","volume":"21","author":"F Da\u00efkha-Dahmane","year":"2006","unstructured":"Da\u00efkha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R . Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 2006; 21: 729\u2013732.","journal-title":"Pediatr Nephrol"},{"key":"BFhr201512_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00404-011-2027-2","volume":"284","author":"F Esposito","year":"2011","unstructured":"Esposito F, Galfetti M, Lava SA, Balestra B, Bianchetti MG . Fetopathy probably associated to self-medication with a blocker of the renin-angiotensin system. Arch Gynecol Obstet 2011; 284: 1321.","journal-title":"Arch Gynecol Obstet"},{"key":"BFhr201512_CR17","first-page":"295","volume":"2","author":"E Georgaki-Angelaki","year":"2009","unstructured":"Georgaki-Angelaki E, Stergiou N, Naoum E, Papassotiriou I, Anagnostakou M . Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature. Nephrol Dial Transplant Plus 2009; 2: 295\u2013297.","journal-title":"Nephrol Dial Transplant Plus"},{"key":"BFhr201512_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.reprotox.2009.02.004","volume":"28","author":"K Gersak","year":"2009","unstructured":"Gersak K, Cvijic M, Cerar LK . Angiotensin II receptor blockers in pregnancy: a report of five cases. Reprod Toxicol 2009; 28: 109\u2013112.","journal-title":"Reprod Toxicol"},{"key":"BFhr201512_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10194-009-0182-7","volume":"11","author":"K Haaland","year":"2010","unstructured":"Haaland K . Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. J Headache Pain 2010; 11: 167\u2013169.","journal-title":"J Headache Pain"},{"key":"BFhr201512_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S0140-6736(00)04758-9","volume":"357","author":"A Hinsberger","year":"2001","unstructured":"Hinsberger A, Wingen A-M, Hoyer PF . Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1620.","journal-title":"Lancet"},{"key":"BFhr201512_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1447-0756.2008.00762.x","volume":"34","author":"K Kato","year":"2008","unstructured":"Kato K, Okuda M, Ishikawa H, Takahashi T, Hirahara F . Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected. J Obstet Gynaecol Res 2008; 34: 242\u2013246.","journal-title":"J Obstet Gynaecol Res"},{"key":"BFhr201512_CR22","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S0140-6736(00)04757-7","volume":"357","author":"M-A Lambot","year":"2001","unstructured":"Lambot M-A, Vermeylen D, No\u00ebl J-C . Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1619\u20131620.","journal-title":"Lancet"},{"key":"BFhr201512_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(01)05426-5","volume":"358","author":"J Martinovic","year":"2001","unstructured":"Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC . Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358: 241\u2013242.","journal-title":"Lancet"},{"key":"BFhr201512_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00467-008-1091-8","volume":"24","author":"K Miura","year":"2009","unstructured":"Miura K, Sekine T, Iida A, Takahashi K, Igarashi T . Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker. Pediatr Nephrol 2009; 24: 1235\u20131238.","journal-title":"Pediatr Nephrol"},{"key":"BFhr201512_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.reprotox.2010.01.010","volume":"29","author":"PS Munk","year":"2010","unstructured":"Munk PS, vonBrandis P, Larsen A . Reversible fetal renal failure after maternal treatment with Candesartan: a case report. Reprod Toxicol 2010; 29: 381\u2013382.","journal-title":"Reprod Toxicol"},{"key":"BFhr201512_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/BF02730601","volume":"70","author":"B Nayar","year":"2003","unstructured":"Nayar B, Singhal A, Aggarwal R, Malhotra N . Losartan induced fetal toxicity. Ind J Pediatr 2003; 70: 923\u2013924.","journal-title":"Ind J Pediatr"},{"key":"BFhr201512_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.jp.7210871","volume":"23","author":"C Pietrement","year":"2003","unstructured":"Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P . Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 2003; 23: 254\u2013255.","journal-title":"J Perinatol"},{"key":"BFhr201512_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(00)03648-5","volume":"357","author":"H Saji","year":"2001","unstructured":"Saji H, Yamanaka M, Hagiwara A, Ijiri R . Losartan and fetal toxic effects. Lancet 2001; 357: 363.","journal-title":"Lancet"},{"key":"BFhr201512_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/bdra.10081","volume":"67","author":"C Schaefer","year":"2003","unstructured":"Schaefer C . Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003; 67: 591\u2013594.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"BFhr201512_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1471-0528.2004.00525.x","volume":"112","author":"R Serreau","year":"2005","unstructured":"Serreau R, Luton D, Macher M-A, Delezoide AL, Garel C, Jacqz-Aigrain E . Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005; 112: 710\u2013712.","journal-title":"BJOG"},{"key":"BFhr201512_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00467-006-0162-y","volume":"21","author":"GD Simonetti","year":"2006","unstructured":"Simonetti GD, Baumann T, Pachlopnik JM, von Vigier RO, Bianchetti MG . Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan. Pediatr Nephrol 2006; 21: 1329\u20131330.","journal-title":"Pediatr Nephrol"},{"key":"BFhr201512_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14767050500217244","volume":"18","author":"M Vendemmia","year":"2005","unstructured":"Vendemmia M, Garcia-Meric P, Rizzottia A, Boubred F, Lacroze V, Liprandi A, Simeoni U . Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists. J Mater-Fetal Neonat Med 2005; 18: 137\u2013140.","journal-title":"J Mater-Fetal Neonat Med"},{"key":"BFhr201512_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/01.AOG.0000187942.09107.08","volume":"108","author":"JN Bakkum","year":"2006","unstructured":"Bakkum JN, Brost BC, Johansen KL, Johnston BW, Watson WJ . In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. Obstet Gynecol 2006; 108: 739\u2013740.","journal-title":"Obstet Gynecol"},{"key":"BFhr201512_CR34","doi-asserted-by":"publisher","first-page":"624","DOI":"10.4067\/S0034-98872008000500012","volume":"136","author":"HJ Hasb\u00fan","year":"2008","unstructured":"Hasb\u00fan HJ, Vald\u00e9s RE, San Mart\u00edn OA, Catal\u00e1n MJ, Salinas QS, Parra CM . Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy. Report of one case. Rev M\u00e9d Chile 2008; 136: 624\u2013630 (in Spanish).","journal-title":"Rev M\u00e9d Chile"},{"key":"BFhr201512_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/pd.3960","volume":"32","author":"E Spaggiari","year":"2012","unstructured":"Spaggiari E, Heidet L, Grange G, Guimiot F, Dreux S, Delezoide A-L, Muller F . Prognosis and outcome of pregnancies exposed to renin\u2013angiotensin system blockers. Prenat Diagn 2012; 32: 1071\u20131076.","journal-title":"Prenat Diagn"},{"key":"BFhr201512_CR36","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S0140-6736(00)04759-0","volume":"357","author":"NA Chung","year":"2001","unstructured":"Chung NA, Lip GY, Beevers M, Beevers DG . Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1620\u20131621.","journal-title":"Lancet"},{"key":"BFhr201512_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.gyobfe.2007.03.015","volume":"35","author":"N Roger","year":"2007","unstructured":"Roger N, Popovic I, Madelenat P, Mahieu-Caputo D . Fetal toxicity of angiotensin-II-receptor inhibitors. Case report. Gynecol Obstet Fertil 2007; 35: 556\u2013560 (in French).","journal-title":"Gynecol Obstet Fertil"},{"key":"BFhr201512_CR38","first-page":"306","volume":"30","author":"MT Sinelli","year":"2008","unstructured":"Sinelli MT, Cattarelli D, Cortinovis S, Maroccolo D, Chirico G . Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists. Pediatr Med Chir 2008; 30: 306\u2013308.","journal-title":"Pediatr Med Chir"},{"key":"BFhr201512_CR39","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1055\/s-0032-1305063","volume":"137","author":"F Markfeld-Erol","year":"2012","unstructured":"Markfeld-Erol F, Farthmann J, Pr\u00f6mpeler H, Kunze M . Fetal renal failure after intrauterine exposure to inhibitors of the renin-angiotensin system. Dtsch Med Wochenschr 2012; 137: 1297\u20131300 (in German).","journal-title":"Dtsch Med Wochenschr"},{"key":"BFhr201512_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2125.2012.04388.x","volume":"75","author":"M Oppermann","year":"2013","unstructured":"Oppermann M, Padberg S, Kayser A, Weber-Schoendorfer C, Schaefer C . Angiotensin-II receptor 1 antagonist fetopathy\u2014risk assessment, critical time period and vena cava thrombosis as a possible new feature. Br J Clin Pharmacol 2013; 75: 822\u2013830.","journal-title":"Br J Clin Pharmacol"},{"key":"BFhr201512_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/BF03345344","volume":"28","author":"E Boix","year":"2005","unstructured":"Boix E, Zapater P, Pico A, Moreno O . Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005; 28: 1029\u20131031.","journal-title":"J Endocrinol Invest"},{"key":"BFhr201512_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/sj.jhh.1000880","volume":"13","author":"R Mann","year":"1999","unstructured":"Mann R, Mackay F, Pearce G, Freemantle S, Wilton L . Losartan: a study of pharmacovigilance data on 14 522 patients. J Hum Hypertens 1999; 13: 551\u2013557.","journal-title":"J Hum Hypertens"},{"key":"BFhr201512_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/10641950601147937","volume":"26","author":"EY Velazquez-Armenta","year":"2007","unstructured":"Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA . Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007; 26: 51\u201366.","journal-title":"Hypertens Pregnancy"},{"key":"BFhr201512_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.jhh.1001490","volume":"16","author":"PN Biswas","year":"2002","unstructured":"Biswas PN, Wilton LV, Shakir SW . The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England. J Hum Hypertens 2002; 16: 795\u2013803.","journal-title":"J Hum Hypertens"},{"key":"BFhr201512_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2834.2011.01250.x","volume":"19","author":"M Morgan","year":"2011","unstructured":"Morgan M, De Jong-van den Berg LT, Jordan S . Drug safety in pregnancy monitoring congenital anomalies. J Nurs Manag 2011; 19: 305\u2013310.","journal-title":"J Nurs Manag"},{"key":"BFhr201512_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/hr.2014.71","volume":"37","author":"AS Sahay","year":"2014","unstructured":"Sahay AS, Patil VV, Sundrani DP, Joshi AA, Wagh GN, Gupte SA, Joshi SR . A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preelcampsia. Hypertens Res 2014; 37: 753\u2013758.","journal-title":"Hypertens Res"},{"key":"BFhr201512_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bdra.20102","volume":"73","author":"S Alwan","year":"2005","unstructured":"Alwan S, Polifka JE, Friedman JM . Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res Part A 2005; 73: 123\u2013130.","journal-title":"Birth Defects Res Part A"},{"issue":"Pt 2","key":"BFhr201512_CR48","first-page":"F326","volume":"262","author":"HJ Grone","year":"1992","unstructured":"Grone HJ, Simon M, Fuchs E . Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physiol 1992; 262 (Pt 2): F326\u2013F331.","journal-title":"Am J Physiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201512","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:14:57Z","timestamp":1684430097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,19]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFhr201512"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.12","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,19]]},"assertion":[{"value":"14 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}